- Home
- IMRN vs INDP Comparison
IMRN vs INDP Comparison
Compare IMRN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- INDP
- Stock Information
- Founded
- IMRN 1994
- INDP 2000
- Country
- IMRN Australia
- INDP United States
- Employees
- IMRN N/A
- INDP N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- INDP Health Care
- Exchange
- IMRN Nasdaq
- INDP Nasdaq
- Market Cap
- IMRN 9.2M
- INDP 5.0M
- IPO Year
- IMRN N/A
- INDP N/A
- Fundamental
- Price
- IMRN $1.74
- INDP $10.53
- Analyst Decision
- IMRN Strong Buy
- INDP Strong Buy
- Analyst Count
- IMRN 1
- INDP 2
- Target Price
- IMRN $5.00
- INDP $8.50
- AVG Volume (30 Days)
- IMRN 24.7K
- INDP 689.1K
- Earning Date
- IMRN 07-07-2025
- INDP 08-11-2025
- Dividend Yield
- IMRN N/A
- INDP N/A
- EPS Growth
- IMRN N/A
- INDP N/A
- EPS
- IMRN N/A
- INDP N/A
- Revenue
- IMRN $4,048,286.00
- INDP N/A
- Revenue This Year
- IMRN N/A
- INDP N/A
- Revenue Next Year
- IMRN N/A
- INDP N/A
- P/E Ratio
- IMRN N/A
- INDP N/A
- Revenue Growth
- IMRN 82.90
- INDP N/A
- 52 Week Low
- IMRN $1.50
- INDP $7.56
- 52 Week High
- IMRN $2.87
- INDP $66.64
- Technical
- Relative Strength Index (RSI)
- IMRN 58.70
- INDP 49.39
- Support Level
- IMRN $1.68
- INDP $8.71
- Resistance Level
- IMRN $1.94
- INDP $13.44
- Average True Range (ATR)
- IMRN 0.09
- INDP 2.03
- MACD
- IMRN 0.02
- INDP 0.34
- Stochastic Oscillator
- IMRN 76.92
- INDP 24.05
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.